[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20220251A - Nuevos derivados de metilquinazolinona - Google Patents

Nuevos derivados de metilquinazolinona

Info

Publication number
CR20220251A
CR20220251A CR20220251A CR20220251A CR20220251A CR 20220251 A CR20220251 A CR 20220251A CR 20220251 A CR20220251 A CR 20220251A CR 20220251 A CR20220251 A CR 20220251A CR 20220251 A CR20220251 A CR 20220251A
Authority
CR
Costa Rica
Prior art keywords
methylquinazolinone
derivatives
new
compound
formula
Prior art date
Application number
CR20220251A
Other languages
English (en)
Inventor
Cosimo Dolente
Daniel Hunziker
Daniela Krummenacher
Juergen Wichmann
David Stephen Hewings
Piergiorgio Francesco Tommaso Pettazzoni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220251A publication Critical patent/CR20220251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Combines (AREA)
  • Harvester Elements (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona un compuesto novedoso que tiene la Fórmula general (I) o una sal farmacéuticamente aceptable de este. El compuesto de Fórmula (I) se puede utilizar como medicamento
CR20220251A 2019-12-10 2020-12-08 Nuevos derivados de metilquinazolinona CR20220251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10
PCT/EP2020/084976 WO2021116055A1 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Publications (1)

Publication Number Publication Date
CR20220251A true CR20220251A (es) 2022-07-11

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220251A CR20220251A (es) 2019-12-10 2020-12-08 Nuevos derivados de metilquinazolinona

Country Status (18)

Country Link
US (2) US12116349B2 (es)
EP (1) EP4073065A1 (es)
JP (2) JP7108146B2 (es)
KR (1) KR20220110554A (es)
CN (2) CN114787156B (es)
AR (1) AR122351A1 (es)
AU (1) AU2020403443B2 (es)
CA (1) CA3162883A1 (es)
CL (1) CL2022001529A1 (es)
CO (1) CO2022008968A2 (es)
CR (1) CR20220251A (es)
IL (1) IL292161A (es)
MX (1) MX2022006783A (es)
PE (1) PE20221778A1 (es)
TW (1) TW202136245A (es)
UA (1) UA128299C2 (es)
WO (1) WO2021116055A1 (es)
ZA (2) ZA202204675B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006783A (es) 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos derivados de metilquinazolinona.
BR112023025916A2 (pt) * 2021-06-09 2024-02-27 Chugai Pharmaceutical Co Ltd Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
EP4352051A1 (en) * 2021-06-09 2024-04-17 F. Hoffmann-La Roche AG New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
BR112023025738A2 (pt) * 2021-06-09 2024-02-27 Hoffmann La Roche Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
CA3227706A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4426305A1 (en) 2021-11-04 2024-09-11 F. Hoffmann-La Roche AG Novel use of quinazolinone compound for the treatment of cancer
TW202409040A (zh) * 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
WO2024105144A1 (en) 2022-11-18 2024-05-23 F. Hoffmann-La Roche Ag Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
WO2024126634A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Process for the preparation of a quinazolinone derivative
WO2024126660A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN106146484A (zh) 2008-03-17 2016-11-23 埃姆比特生物科学公司 喹唑啉衍生物作为raf激酶调节剂以及它们的方法和用途
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
ES2612885T3 (es) 2012-09-19 2017-05-19 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
TWI812581B (zh) 2015-05-22 2023-08-21 美商普雷辛肯公司 激酶調節及其適應症
PT3359541T (pt) 2015-10-09 2020-11-11 Galapagos Nv Pirazol[3,4-b]piridin-6-carboxamidas n-sulfoniladas e método de utilização
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
JP7539892B2 (ja) 2019-01-03 2024-08-26 ジェネンテック， インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
BR112022010633A2 (pt) 2019-12-10 2022-08-16 Hoffmann La Roche Composto de fórmula, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer de tireoide e invenção
MX2022006783A (es) 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos derivados de metilquinazolinona.
CR20220626A (es) 2020-06-09 2023-01-23 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
WO2022129260A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New aryl-pyrido-pyrimidin-one derivatives
JP2023554442A (ja) 2020-12-18 2023-12-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規キナゾリノン誘導体
IL308748A (en) 2021-06-08 2024-01-01 C4 Therapeutics Inc Therapeutic agents for knockdown of mutant BRAF
CA3241856A1 (en) 2021-12-08 2023-06-15 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide

Also Published As

Publication number Publication date
MX2022006783A (es) 2022-07-11
PE20221778A1 (es) 2022-11-16
CN114787156B (zh) 2024-07-26
US20240174621A1 (en) 2024-05-30
ZA202206923B (en) 2024-10-30
JP7108146B2 (ja) 2022-07-27
AU2020403443B2 (en) 2023-02-23
BR112022011123A2 (pt) 2022-08-23
CN118791472A (zh) 2024-10-18
UA128299C2 (uk) 2024-05-29
EP4073065A1 (en) 2022-10-19
US12116349B2 (en) 2024-10-15
IL292161A (en) 2022-06-01
KR20220110554A (ko) 2022-08-08
US20220298119A1 (en) 2022-09-22
JP2022124458A (ja) 2022-08-25
ZA202204675B (en) 2022-12-21
AU2020403443A1 (en) 2022-05-12
WO2021116055A1 (en) 2021-06-17
CN114787156A (zh) 2022-07-22
JP2022531609A (ja) 2022-07-07
TW202136245A (zh) 2021-10-01
AR122351A1 (es) 2022-09-07
CL2022001529A1 (es) 2023-02-10
CA3162883A1 (en) 2021-06-17
CO2022008968A2 (es) 2022-07-19

Similar Documents

Publication Publication Date Title
ZA202206923B (en) New methylquinazolinone derivatives
PH12020500673A1 (en) Compounds
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
EA202193015A1 (ru) Ингибиторы cdk
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2021007247A (es) Derivados de rapamicina.
MX2021012105A (es) Compuestos de pirrol.
CR20220029A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
MY193239A (en) Novel b-lactamase inhibitors
SG11201903801YA (en) Pyridone compound as c-met inhibitor
PH12019550154A1 (en) Azetidine derivative
WO2018039077A8 (en) Therapeutic compounds
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2021014458A (es) Compuestos triciclicos.
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
MX2022006776A (es) Composiciones farmaceuticas oftalmicas.
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
MX2022007634A (es) Inhibidores de egfr.
SA522431572B1 (ar) مركب بيريميدين-5-كربوكساميد
SA119400353B1 (ar) مشتق بيرازول مستبدل